Abstract | Multiple sclerosis (MS) is considered to be a predominantly T-cell-mediated disease, and emerging evidence indicates that dendritic cells have a critical role in the initiation and progression of this debilitating condition. Dendritic cells are specialized antigen-presenting cells that can prime naive T cells and modulate adaptive immune responses. Their powerful biological functions indicate that these cells can be exploited by immunotherapeutic approaches. Therapies that inhibit the immunogenic actions of dendritic cells through the blockade of proinflammatory cytokine production and T cell co-stimulatory pathways are currently being pursued. Furthermore, novel strategies that can regulate dendritic cell development and differentiation and harness the tolerogenic capacity of these cells are also being developed. Here, we evaluate the prospects of these future therapeutic strategies, which focus on dendritic cells and dendritic cell-related targets to treat MS.
Introduction multiple sclerosis (ms) is considered to be an antigendriven, predominantly t-cell-mediated autoimmune disease. this view is based on numerous clinical and experimental findings. For example, analysis of infiltrating cells in the brains and cerebrospinal fluid (CsF) of patients with ms has revealed that t cells are positively associated with inflammatory ms lesions. Data derived from studies of an animal model of ms-experimental autoimmune encephalomyelitis (eae)-have shown that eae can be induced by adoptive transfer of myelin-specific CD4 + t cells from sick to naive animals. 1 Certain mHC class ii alleles, in particular the DRB1*1501 allele, are genetic risk factors for ms development.
2,3 Furthermore, analysis of CsF and brain tissue from patients with ms has provided evidence of clonal expansion in both t and B cell populations, indicating that clonal reactivity to a number of unknown disease-relevant target antigens occurs in this condition. [4] [5] [6] [7] longitudinal studies have also shown that individual t cell clones can be identified in the blood of patients with ms over long periods of time, [8] [9] [10] indicating that a strong, persisting response and/or ongoing antigen exposure is a prominent feature of this disease.
Dendritic cells are professional antigen-presenting cells that can modulate adaptive immune responses. these cells pro cess antigens and present antigen peptide fragments on
mHC molecules to naive t cells. By secreting a number of cytokines, dendritic cells direct naive t cells towards differentiation into various subtypes of t helper (t H ) cells (Figure 1).
11 this so-called t-cell polarization induces cell-mediated protection, and guides these immune cells to particular locations where the immune response is most needed. in addition to initiating and enhancing immunogenicity, dendritic cells maintain central and peripheral t-cell tolerance-the process that eliminates or neutralizes autoreactive cells-by deleting and/or silencing autoreactive t cells, or by stimulating the genesis of regulatory t cells that inhibit autoreactive immune responses. 12 in fact, the tolerogenic capacity of dendritic cells is considered to be particularly important during the steady state of autoimmune diseases, when infection and inflammation are absent, in order to avoid inappropriate responses to 'harmless' antigens. understanding how these cells regulate adaptive immune responses has aided the develop ment of a new generation of immunotherapies, and the efficacy of these novel treatments is currently being investigated in infectious, malignant and autoimmune diseases. 13, 14 in this review, we provide an overview of dendritic cell function, particularly during autoimmune diseases of the Cns, and describe how these cells are being targeted by immunologically based therapies.
Innate and adaptive immunity
Dendritic cells were originally discovered and named for their stellate, tree-like shapes by steinman and Cohn in 1973, 15, 16 and are abundant at both internal and external body surfaces. these cells sense environmental, microbial and endogenous antigens and, after migrating to the lymphoid organs, they present the processed antigens to naive t cells to induce antigen-specific immunity or tolerance. endocytic receptors, such as lectins, increase the efficacy www.nature.com/nrneurol of antigen uptake by dendritic cells. these receptors, which include the type 1 transmembrane proteins DeC-205 (CD205) and macrophage mannose receptor 1 (mmr, or CD206), and type 2 trans membrane proteins such as dendritic cell-specific intercellular ad hesion molecule-3-grabbing non-integrin (DC-siGn, or CD209), langerin (CD207) and C-type lectin domain family 4 member a, deliver the antigens to processing compartments within the dendritic cell, where the processed antigen fragments are loaded onto mHC molecules. through the use of monoclonal antibodies that bind to these receptors as surrogate ligands, dendritic cells can be efficiently targeted by vaccine antigens.
14 For example, the immunogenicity of retroviral vectors can be increased by engineering the retroviral vector envelope to target the DC-siGn protein on dendritic cells. 17 the efficacy of Hiv Dna vaccines can also be improved by coupling the antigen to a DeC-205-specific antibody. 18 Tnaive  TH1  TH2  T H 17   TGF-β  IL-4  IL-10   IFN-γ, IL-2 IL-4, IL-5, IL-13  IL-17, IL-21, IL-22   IL-12  IL-18  IL-1  IL-6  TGF-β  IL-21  IL-23 Peptide fragment MHC most dendritic cells reside within the body in a socalled immature state. in this state, these cells are devoid of many of the features and processes that lead to a strong t-cell response, such as elevated mHC presentation, costimulatory molecule expression and cytokine production. nevertheless, immature dendritic cells are capable of detecting and sequestering antigens. activation of dendritic cells by various types of stimuli, including microbial ligands and inflammatory cytokines, leads to the maturation of these immune cells. During maturation, antigen-mHC complexes are transported to the dendritic cell surface, co-stimulatory molecules (CD80 and CD86) that are necessary for t-cell activation and survival are upregulated, and dendritic cell cytokine production is initiated. Dendritic cell cytokine production is an important component of the immune system, as these signaling molecules are required for t-cell differentiation and assist in the activation of antibody-producing B lineage cells.
Key points
Classification of dendritic cells is based on the differential expression of cell surface markers, many of which are involved in recognition of infectious pathogens and antigen presentation. Human dendritic cells can be divided into myeloid (CD11c 19,20 on the basis of their phenotype and functional properties, dendritic cells can be subdivided further as outlined in Box 1, and the different cell types probably recognize distinct pathogens and/or antigens and initiate and regulate distinct innate and adaptive responses. 21, 22 in the absence of immune activation, most dendritic cells residing in lymphoid organs are derived from a blood-borne precursor, 23, 24 and the development of these cells is driven by fms-related tyrosine kinase 3 ligand (Flt3l). [25] [26] [27] During inflammation and infection, how ever, dendritic cells derived from monocyte precursors are mobilized by numerous c ytokines, including granulocyte-macrophage colony-stimulating factor (GmCsF) and macrophage colony-stimulating factor (m-CsF). 28, 29 thus, the term 'dendritic cell' encompasses a group of heterogeneous antigen-presenting immune cells. nevertheless, the dif ferent populations of dendritic cells share characteristic features of the dendritic cell lineage, such as the capacity to process and to present antigens, high levels of mHC class ii expression, and the ability to prime naive t cells.
Autoimmune CNS inflammation
the presence of dendritic cells in vascular-rich regions of the healthy Cns such as perivascular spaces, the choroid plexus, and the meninges indicates that they might have an immune surveillance role in the Cns. 30, 31 Dendritic cells accumulate in the Cns parenchyma during a wide range of inflammatory insults, 31 and they are also present in inflammatory ms lesions. 32, 33 whether dendritic cells in areas of inflammation within the Cns are derived from resident CD11b 
CD11c
-microglia or whether they infiltrate into these areas from a blood-borne population is an issue of considerable debate. studies in CD11c reporter mice have identified a unique population of 'ramified' CD11b + CD11c + mHC-ii -cells residing in various regions of both developing and adult brain parenchyma. 34 on interferon (iFn)-γ treatment, these cells upregulated mHC class ii molecules and were shown to stimulate t cells effectively. 35 similar findings were observed when microglia residing in the Cns were treated with dendritic cell differentiation factors such as Gm-CsF, 36, 37 indicating that some microglial cells are able to acquire dendritic cell-like functions.
During the development of eae, CD11c + dendritic cells alone are sufficient to present antigens to primed myelin-reactive t cells, mediate Cns inflammation and initiate disease progression. [38] [39] [40] Peripherally derived myeloid dendritic cells seem to be superior at inducing the activation and differentiation of Cns-infiltrating myelin-specific t cells, when compared with plasmacytoid dendritic cells and other myeloid cells that reside or accumulate within the Cns during eae development. this superior ability to activate t cells is, presumably, a result of their enhanced production of t-cell differentiating cytokines. 41 other studies indicate that dendritic cells can, depending on their location or differen tiation state, prevent the development of eae. 42 For example, thymus-derived dendritic cells loaded with myelin antigen and injected intravenously into eaesusceptible hosts were shown to inhibit disease development. this protection was lost in thymectomized animals, indicating that dendritic cells that migrate to the thymus can negatively regulate encephalitogenic t cells. 43 evidence suggests that mouse plasmacytoid dendritic cells also negatively regulate encephalitogenic CD4 + t-cell responses. 41 Patients with ms seem to have higher titers of bloodderived myeloid dendritic cells, which express the maturation marker CD80 and secrete interleukin (il)-12 and tumor necrosis factor (tnF), than healthy controls. 44 Furthermore, dendritic cells differentiated in vitro from blood monocytes taken from patients with ms secrete higher levels of proinflammatory cytokines il-6, 45 tnF 45 and/or il-23 than the same cells taken from healthy indivi duals. 46 altered plasmacytoid dendritic cell phenotypes primarily characterized by decreased expression of maturation markers have also been reported in patients with ms. [47] [48] [49] in summary, peripherally derived dendritic cells that infiltrate the Cns seem to be crucial for eae development. moreover, evidence is emerging that overproduction of particular cytokines by certain dendritic cell subtypes drives autoimmune Cns inflammation. By contrast, some dendritic cells located in lymphoid organs have the capacity to confer antigen-specific tolerance to t cells and prevent the development of ms. owing to the central role of dendritic cells in priming t cells and their capacity to confer antigen-specific tolerance, immunotherapies that target these cells by either inhibiting their immunogenic potential or enhancing their tolerogenic functions could provide substantial benefits to patients with ms. indeed, several emerging immunotherapies that have been developed for the treatment of various autoimmune diseases specifically target dendritic cell cytokine production or antigen presentation. Before we evaluate these novel strategies, we will discuss evidence that approved ms therapies exert their beneficial effects via interactions with both dendritic cells and the innate immune system. Modulation of dendritic cell function regulatory-approved ms therapies, such as iFn-β1a and iFn-1b (iFn-β), glatiramer acetate, mitoxantrone and natalizumab, are all reasonably effective at attenuating disease progression. these compounds, as well as the three monoclonal antibodies that are currently under investigation for ms (rituximab, alemtuzumab and daclizumab) and the two orally available treatments (fingolimod and cladribine) that have already proved to be effective in large phase iii ms clinical trials, were originally designed to inhibit autoreactive adaptive immune responses. immunological studies, however, have indicated that the mechanisms of action of both approved and potential ms therapies are complex. the pharmacological actions of these therapies, at least in part, affect innate immune functions, such as dendritic cell-mediated polariza tion of effector t cells or dendritic cell-mediated expansion of regulatory immune cell compartments. iFn-β, a pleiotropic cytokine with antiviral activity that is secreted by plasmacytoid dendritic cells, became the first drug approved for the treatment of relapsing-remitting ms. studies indicate that its complex mechanisms of action in ms include an inhibitory effect on dendritic cellmediated t H 17-cell differentiation. 50 thus, in addition to the reported direct effects on t effector cells such as t H 17 lymphocytes, 51 iFn-β also seems to downregulate the expression of t H 17-cell-polarizing cytokines. 52 Furthermore, the clinical response to iFn-β treatment in patients with ms has been associated with changes in dendritic cell function. Genome-wide expression profiling and functional studies in iFn-β responders versus non responders revealed that the latter had higher levels of dendritic cell co-stimulatory molecules such as CD86 on myeloid dendritic cells before initiation of treatment. this finding suggests that patients with ms with more pre activated dendritic cells are less susceptible to iFn-β therapy. 53 Glatiramer acetate was the first non-iFn therapy approved for the treatment of ms. this compound is a synthetic mixture of four amino acids, glutamic acid, lysine, alanine and tyrosine, in a molar ratio of 1.5:3.6:4.6:1.0. this ratio is equivalent to the molar ratio of the four most abundant amino acids in myelin basic protein (mBP), a presumed target antigen in ms. Glatiramer acetate is believed to induce the expansion of a population of glatiramer acetate-reactive anti-inflammatory t H 2 cells through interference with peptide-mHC binding on antigen-presenting cells. Glatiramer acetate also influences dendritic cellmediated t-cell polarization. Both vieira et al. 54 and Kim et al. 55 have showed that glatiramer acetate treatment in humans can enhance and inhibit il-10 and il-12 production, respectively, in monocyte-derived dendritic cells and blood monocytes, both of which seem to favor t H 2-mediated differentiation of naive t cells. the terms 'type 1' and 'type 2' in relation to antigen-presenting cells has been introduced to describe the ability of these cells to polarize either t H 1 or t H 2 cells. in line with the aforementioned studies in humans, weber et al. showed in experimental animal models of ms that glatiramer acetate promoted the development of type 2 antigen-presenting cells, which induced differentiation of t H 2 cells and regulatory t cells. 56 notably, adoptive transfer of glatiramer acetate-induced type 2 antigen-presenting cells reversed eae and suppressed pathogenic t-cell development. 56 in addition, Burger et al. have reported that glatiramer acetate inhibits proinflammatory monocyte function by stimulating the production of il-1 receptor antagonist (il-1ra) by human monocytes.
57 not all the studies mentioned above directly addressed the role of dendritic cells in ms, but they clearly extended the concept that glatiramer acetate's mechanisms of action include promotion of the anti-inflammatory functions of antigen-presenting cells.
the humanized monoclonal antibody natalizumab was originally designed to block trafficking of immune cells into the Cns. indeed, the efficacy of natalizumab in ms is associated with a prolonged decrease in CsF leukocyte counts. 58 natalizumab achieves this feat by preventing the adhesion molecule very late activation antigen 4 (vla-4) from interacting with its natural ligands, vascular cell adhesion molecule 1 (vCam-1) and fibronectin. Furthermore, in addition to its effect on adaptive immune cells, natalizumab has been shown to markedly reduce the number of dendritic cells in cerebral perivascular spaces, which suggests that its mechanism of action involves inhibition of dendritic cell or dendritic cell precursor recruitment into the Cns. 59 none of the approved ms therapies specifically targets dendritic cells. nevertheless, a number of dendritic cellbased therapies have been tested in eae and other animal models of ms, and a few of these therapies are currently being investigated or are already approved in other human autoimmune diseases, such as rheumatoid arthritis.
Dendritic cell-targeted therapies
Potential autoimmune diseases therapies that target dendritic cells aim to either inhibit immunogenic dendritic cell functions or support their tolerogenic potential (Figure 2) . most strategies involve the use of monoclonal antibodies, which target molecules selectively expressed by these cells.
Targeting cytokine production
Cytokines released by dendritic cells stimulate and instruct t cells where to go and what to do. on matura tion, dendritic cells produce an array of potent proinflammatory molecules, including il-1, il-6, il-12 and tnF (Figure 1) . the so-called il-1 family of cyto kines includes the proinflammatory members il-1α, il-1β, il-18 and il-33, as well as molecules that suppress inflammation such as il-1ra, which competes with il-1 for receptor binding. 60 owing to its role in mediating autoinflammatory diseases, il-1β is the most intensively studied member of this family. il-1α and il-1β knockout mice are resistant to eae induction. 61 il-1 is abundantly expressed by infiltrating myeloid cells and local microglia in inflammatory ms lesions. 62 on the basis of positive clinical trials, a recombinant version of il-1ra-anakinra-has been approved for the treatment of patients with rheumatoid arthritis who do not respond to standard therapy. like other pharmacological agents that block key inflammatory cytokines and pathways, the most important safety issues associated with anakinra use reviews relate to increased risk of serious infections, and occurrence of malignancies owing to impaired immune function. to date, the safety and efficacy of anakinra and other compounds that target il-1 have not been evaluated in patients with ms. 60 il-6 is produced and secreted by innate immune cells and affects lymphocyte function. il-6 knockout mice are resistant to eae induction; 63 however, eae susceptibility can be restored by exogenous administration of this mo lecule. 64 During initiation and progression of eae, il-6 seems to promote disease pathology by increasing the production of pathogenic effector t cells and decreasing the numbers of regulatory t cells. 65 Blocking il-6 function, therefore, is a reasonable therapeutic strategy for limiting t-cell-mediated autoimmunity. in fact, tocilizumab, a humanized monoclonal antibody that competes with il-6 for receptor binding, has been approved by the FDa for the treatment of rheumatoid arthritis. adverse events associated with tocilizumab use are similar to those associated with anakinra use, and study participants who were given tocilizumab had an increased risk of serious infection compared with study participants who received placebo. 66 to our knowledge, the efficacy of tocilizumab or any other molecule that specifically blocks il-6 function has not been tested in patients with ms.
il-12 and il-23 are related heterodimeric cytokines that share a common subunit (p40) and have either p35 (il-12) or p19 (il-23) as a second subunit. il-12 signaling induces t H 1 differentiation, whereas il-23 seems to support the differentiation and maintenance of il-17 producing cells. Both p40 and p19 have been detected in demyelinating ms lesions within the brain, 67, 68 and knockout mice lacking either p40 or p19 are resistant to eae. 69, 70 surprisingly, neutralization of the p40 subunit by the monoclonal antibody ustekinumab-which is effective in patients with psoriasis or psoriatic arthritis, and in patients with Crohn disease-failed to show any efficacy in patients with relapsing-remitting ms. 71 this finding suggests that cytokine-mediated immuno pathology observed in eae models of ms cannot be simply extrapolated to the human disease. studies investigat ing two important t-cell effector cytokines further support this assertion. For example, iFn-γ has been shown to be partially protective in eae, but its therapeutic use in patients with ms has led to disease exacerbation. 72 similarly, tnF is thought to have a pathogenic role in eae animals, but tnF neutraliza tion in patients with ms has been shown to exacerbate disease symptoms. 73 However, poor Cns availability of the systemically admini stered p40 targeting antibody or the short study period (24 weeks) could have contributed to the ne gative results of the aforementioned clinical trial. 71 the discovery of cytokines that promote dendritic cell development and differentiation, such as Flt3l, Gm-CsF and m-CsF, has had a positive impact on dendritic cell research. 74 Gm-CsF is produced by stromal cells, activated t cells and natural killer cells and is, therefore, enriched at sites of inflammation. 75 although Gm-CsF is not essential for steady-state dendritic cell development, 76 it supports dendritic cell differentiation from monocyte progenitors during inflammation and infection, 28, 29, 75 and Alternative strategies have been designed to limit the immunogenic capacity of dendritic cells by either inhibiting their production of inflammatory cytokines that activate T cells, or by reducing the release of dendritic cell co-stimulatory molecules, which induce generation and activation of effector T cells. Most of these strategies involve the use of monoclonal antibodies, which target molecules selectively expressed by dendritic cells. Abbreviations: FLT3-L, fms-related tyrosine kinase 3 ligand; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; M-CSF, macrophage colony-stimulating factor; TCr, T cell receptor; T EFF , effector T cell; T rEG , regulatory T cell. reviews recruitment of blood monocytes seems to sustain autoimmune tissue damage during eae. 77 therefore, inhibition of inflammation-induced dendritic cell differen tiation from monocytes through blockade of Gm-CsF signaling might have therapeutic merit in autoimmune diseases. this approach is under investigation in two phase ii clini cal trials in patients with ra, in which the efficacy of two antibodies (mor103 and KB003) designed to block Gm-CsF signaling are being evaluated. therapies that specifically target dendritic cell homeo stasis and inflammation-induced dendritic cell generation have not yet been initiat ed in ms.
Targeting co-stimulation During t-cell recognition of peptide-mHC complexes presented by dendritic cells, co-stimulatory molecules can provide positive signals that promote t-cell activation or negative signals that inhibit t-cell responses. the B7-CD28 superfamily, a tumor necrosis factor receptor subfamily that lack death domains, includes a number of well-characterized t-cell co-stimulatory molecules that regulate t-cell activation as well as tolerance. two such co-stimulatory molecules are the proteins B7-1 (CD80) and B7-2 (CD86), which bind to CD28 on t cells to support the activation of these cells. By blocking the binding of B7 proteins to CD28, a fusion protein called cytotoxic t-lymphocyte antigen 4 (Ctla4-ig), which binds to B7-1 and B7-2, is effective at attenuating tissue inflammation in many preclinical models of autoimmune disease. in fact, this compound has now been approved for the treatment of patients with rheumatoid arthritis. 78 ,79 an open-label phase i clinical trial has also shown that intravenous infusions of Ctla4-ig are well tolerated in patients with ms. Future studies will show whether B7-CD28 blockade, as well as other new co-stimulatory inhibitors, such as anti-CD40 and CD154 antagonists, will prove to be safe and effective in ms.
Targeting tolerogenic functions
Dendritic cells must undergo terminal differentiation or maturation in order to coordinate protective immunity. maturation is induced by a spectrum of environmental and endogenous stimuli, including toll-like receptor and tnF-receptor ligands. in the steady state when no matura tion stimuli are present, however, dendritic cells can induce t-cell tolerance. in the first human study to test tolerogenic dendritic cell functions, subcutaneous application of immature dendritic cells, previously incubated with an influenza matrix protein (mP)-derived peptide, led to a transient inhibition of pre-existing mP-specific effector t-cell functions. mP-specific il-10-producing cells were also upregulated, and were shown to have reduced iFn-γ production and to lack apoptotic activity. 80 experimental models of autoimmune Cns inflammation have provided evidence that antigen-specific t-cell tolerance can be induced by oral administration of myelin antigens. 81, 82 For example, altered peptide ligands (aPls) derived from myelin antigens, which interfere with the interaction between mHC-peptide complexes and encephalitogenic t cells, have been shown to induce t-cell tolerance. 83, 84 similarly, administration of high doses of either myelin peptides or soluble mHC-myelin peptide complexes, which primarily eliminate or inactivate myelin-specific t cells, have been shown to be effective in experimental models of autoimmune diseases. [85] [86] [87] ongoing clinical trials are evaluating the safety, toler ability and efficacy of antigen-specific therapies in ms. 88, 89 in a small, 24 month randomized controlled trial, intravenous injection of soluble mBP peptide (mBP8298), administered without adjuvants, was well tolerated in patients with primary progressive or secon dary progressive ms. this potential therapy also had moderate effects on disease progression-determined by changes in expanded Disability status scale scores-in patients carrying the ms-associated mHC haplotypes DR2 and/or DR4. 90 Dna vaccines might also provide antigen-specific tolerance. 91, 92 in a randomized controlled phase i/ii trial, intramuscular administration of a Dna vaccine encoding full-length human mBP (BHt-3,009) in patients with relapsing-remitting and secondary progressive ms was well tolerated, led to a decrease in proliferation of and iFn-γ production in myelin-reactive CD4 + t cells, and pro vided favorable trends on brain mri metrics. 93 large phase ii and phase iii clinical trials are currently underway to test the effect of soluble mBP peptide admini stration and mBP Dna vaccination in patients with relapsing-remitting and secondary progressive ms.
a third strategy that is currently being pursued to increase dendritic cell tolerogenicity involves reinfusing peripheral blood lymphocytes that have been chemically coupled with peptides from supposedly immunodominant myelin antigens. 94 Preclinical experiments in animal models of ms have shown that this approach can prevent disease onset and ameliorate disease progression. [95] [96] [97] [98] an open-label phase i trial designed to test the safety and efficacy of this strategy in patients with relapsing-remitting ms has been initiated. 89 we hypothesize that the approaches mentioned above involve dendritic cells that are able to phagocytose the externally administered myelin peptides or protein. in preclinical animal models of ms, the administration of partly matured dendritic cells loaded with myelin peptide can suppress eae development. 99 notably, targeting of antigens to dendritic cells by coupling them to antibodies raised against specific dendritic cell receptors, such as the decalectin DeC-205, increases the efficacy by which antigens are delivered to the immune system >100-fold. [100] [101] [102] [103] [104] Hawiger et al. have shown that mice preinjected with a monoclonal antibody to DeC-205, coupled with the encephalitogenic moG peptide, were completely resistant to eae development induced by subsequent moG immunization.
105 similar targeting strategies have also been developed for mmr, 106 DC-siGn, 107 dendritic cell immunoreceptors, 21,108 dendritic cell nK lectin group receptor-1, 109 dendritic cell immunoactivating receptor 1, 110 and C-type lectin domain family 4 member C.
one potential obstacle in translating these tolerization strategies into the clinic is the fact that patients with ms have increased levels of myeloid dendritic cells that express co-stimulatory t-cell-activating molecules. the enhanced levels of myeloid dendritic cells in patients with ms presumably result directly from dendritic cell maturation induced by chronic autoimmune inflammation. [44] [45] [46] antigen-specific tolerization strategies, even in the absence of adjuvants, could, therefore, elicit unwanted and potentially deleterious t-cell effector responses. in proofof-concept studies, in which patients with ms received an aPl based on the amino acid sequence mBP 83-99 , 116,117 some patients experienced unexpected disease exacerbations, which could be linked to unforeseen immunogenic effects of this aPl in vivo. 117 limiting the immunogenic potential of dendritic cells by blocking the production or signaling of pro inflammatory cytokines such as il-6 might reduce the risk of trigger ing pathogenic t-cell responses by antigen-specific therapies. 63 an alternative approach is to support tolerogenic dendritic cell functions in a way that does not involve exposing these cells to antigens. inhibition of dendritic cell maturation could be one such approach. [118] [119] [120] small-molecule inhibitors of signaling molecules such as Janus kinase 3 and spleen tyrosine kinase, which are involved in dendritic cell maturation, 121, 122 are currently under investigation in patients with rheumatoid arthritis and psoriasis.
123,124

Conclusions
Dendritic cells are central to the induction of immunity and the regulation of immune tolerance. in experimental models of autoimmune diseases including eae, dendritic cells induce and maintain pathogenic effector t-cell functions. whether dendritic cells initiate adaptive auto immunity in ms or whether these cells contribute to disease progression at later stages is unknown. Furthermore, we still have much to learn about the functions of the different types of dendritic cell, and their effects on t-cell mobilization in intact human lymphoid tissue and during chronic inflammation. nevertheless, their powerful biological functions indicate that these cells are key targets for immunotherapeutic approaches. therapies that inhibit immuno genic dendritic cell functions through blockade of pro inflammatory cytokine production and inhibition of co-stimulatory molecules are being investigated. other potential therapies that affect dendritic cell development and differentiation, and harness the tolerogenic capacity of these cells, are also under study. thus, the tools to harness dendritic cell functions in order prevent or limit autoimmune Cns inflammation are available, and will probably become more specific and effective in the near future. these pharmacological agents will allow us to address whether dendritic cell-targeting strate gies, either alone or in combination with established therapies, will improve our ability to limit disease activity and progression in patients with ms.
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